Search

Alkermes PLC

Chiusa

SettoreSettore sanitario

49.21 0.88

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

48.37

Massimo

49.46

Metriche Chiave

By Trading Economics

Entrata

67M

501K

Vendite

103M

496M

P/E

Media del settore

131.184

57.371

EPS

0.52

Margine di Profitto

0.101

Dipendenti

2,050

EBITDA

76M

54M

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+19.19% upside

Dividendi

By Acuity

Utili prossimi

27 ott 2026

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-426M

8.4B

Apertura precedente

48.33

Chiusura precedente

49.21

Notizie sul Sentiment di mercato

By Acuity

10%

90%

6 / 340 Classifica in Healthcare

Alkermes PLC Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

21 ago 2026, 19:51 UTC

Alkermes Plc's shares are higher, supported by strong biotechnology sector momentum, though the stock is pulling back from earlier session highs.

20 ago 2026, 20:01 UTC

Alkermes Plc shares are lower, impacted by broader weakness in the Biotechnology sector. The stock is trading below its 20-day moving average.

19 ago 2026, 19:26 UTC

Alkermes Plc is trading higher, maintaining momentum since Tuesday's close, despite no specific news driving the price movement.

18 ago 2026, 19:16 UTC

News

Alkermes Plc shares are lower after an insider sold 7,576 shares at prices between $49.19 and $49.65, raising investor concerns about the outlook.

17 ago 2026, 23:31 UTC

Alkermes Plc shares are higher in after-market trading, reflecting a cumulative gain since Monday's close amid broader market volatility and fluctuating crude oil prices.

14 ago 2026, 19:46 UTC

Alkermes Plc shares are lower today amid broader market weakness following a reported decline in U.S. retail sales for July.

13 ago 2026, 19:26 UTC

Alkermes Plc shares are lower during Thursday's session, breaking a trend of higher closes. Broader market sentiment may be influenced by rising jobless claims.

12 ago 2026, 21:51 UTC

Alkermes shares are higher in after-market trading, reflecting positive momentum amid easing inflation concerns and a broader market recovery.

11 ago 2026, 19:26 UTC

Alkermes Plc shares are trading lower today, remaining near the lower end of their one-month range amid a lack of specific company news.

10 ago 2026, 19:46 UTC

Alkermes shares are advancing today, despite earlier fluctuations and no specific news. Broader market uncertainty follows a decline in U.S. employment reported last Friday.

6 ago 2026, 19:36 UTC

Alkermes Plc shares are lower today, reflecting unusual volatility and trading significantly below the 20-day moving average. No specific news was identified.

5 ago 2026, 19:56 UTC

Alkermes Plc shares are lower Wednesday, continuing a decline since Tuesday's close, despite broader market optimism from falling oil prices and potential diplomatic resolutions.

4 ago 2026, 19:26 UTC

News

Alkermes Plc shares are lower today amid concerns over recent insider sales by executives, despite the company's gross margin of 80.22%.

3 ago 2026, 20:02 UTC

Alkermes shares are higher today, driven by significant gains in the overall market and major technology stocks, despite earlier session pullbacks.

31 lug 2026, 19:36 UTC

Alkermes Plc shares are lower today, impacted by declines in the Biotechnology sub-sector. The stock remains below its 20-day moving average.

30 lug 2026, 19:58 UTC

Alkermes Plc shares are higher during Thursday's session, reflecting a broader recovery in tech shares despite remaining below the 20-day moving average.

29 lug 2026, 20:03 UTC

News
Macro Event

Shares declining despite price target increases from JP Morgan, Baird.

28 lug 2026, 20:02 UTC

News
Event

Alkermes Plc shares are lower after reporting second-quarter earnings of 0 cents per share, below the consensus estimate of 29 cents.

24 lug 2026, 19:46 UTC

Alkermes Plc shares are lower today, pulling back after an early high. No specific news has been identified to explain the decline.

22 lug 2026, 19:36 UTC

Alkermes Plc shares are lower today, despite an earlier session high, amid rising crude oil prices and concerns over potential supply disruptions.

21 lug 2026, 18:46 UTC

Alkermes shares are higher today, supported by improved market sentiment and renewed interest in AI stocks. The asset is trading near its one-month range high.

20 lug 2026, 22:01 UTC

Alkermes Plc shares declined after-market, retracing from earlier peaks. The asset is currently below its 20-day moving average.

Confronto tra pari

Modifica del prezzo

Alkermes PLC Previsione

Obiettivo di Prezzo

By TipRanks

19.19% in crescita

Previsioni per 12 mesi

Media 58.25 USD  19.19%

Alto 65 USD

Basso 38 USD

Basato su 12 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Alkermes PLC - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

12 ratings

9

Acquista

2

Mantieni

1

Vendi

Sentiment

By Acuity

6 / 340 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove rialziste molto forti

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sopra la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Alkermes PLC

Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS). The Company's products include ARISTADA, VIVITROL, INVEGA SUSTENNA, XEPLION, INVEGA TRINZA, TREVICTA, RISPERDAL CONSTA, AMPYRA, FAMPYRA, BYDUREON, Aripiprazole lauroxil, ALKS 5461, ALKS 3831, ALKS 8700, ALKS 6428, ALKS 4230 and ALKS 7119. The Company's product platforms include injectable extended-release microsphere technology, LinkeRx technology, NanoCrystal technology and oral controlled release (OCR) technology. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia.
help-icon Live chat